<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564521</url>
  </required_header>
  <id_info>
    <org_study_id>2006-108-1134</org_study_id>
    <nct_id>NCT04564521</nct_id>
  </id_info>
  <brief_title>Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma.</brief_title>
  <official_title>The Effect of Nitroglycerin on the Incidence of Cardiorespiratory Side Effect During the Intra-arterial Chemotherapy in Pediatric Patients With Retinoblastoma: a Randomized, Double-blind, Placebo-controlled, Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of intravenously infused&#xD;
      nitroglycerin on the incidence of the cardio-respiratory side effects during the&#xD;
      intra-arterial chemotherapy for retinoblastoma in pediatric patients.&#xD;
&#xD;
      The intra-arterial chemotherapy at the ophthalmic artery is an important treatment option for&#xD;
      retinoblastoma. However, the cardio-respiratory side effects (sudden onset of bradycardia,&#xD;
      hypotension, a severe decrease in the compliance of lung, hypoxia) occasionally occurs during&#xD;
      catheter manipulation in the ophthalmic artery. One of the purported mechanisms of&#xD;
      cardio-respiratory side effects is vagal activation from the activation of trigeminal&#xD;
      ganglion by afferent signals from the ophthalmic artery. Additionally, the chemotherapy agent&#xD;
      can cause intra-arterial retinal precipitates. Therefore, it is expected that the dilation of&#xD;
      the retinal artery may reduce the cardio-respiratory side effects and intra-arterial retinal&#xD;
      precipitates.&#xD;
&#xD;
      The hypothesis of this study is that the intravenously infused nitroglycerin will increase&#xD;
      the compliance of the ophthalmic and retinal artery and decrease vagal stimulation and&#xD;
      cardio-respiratory side effects during catheter manipulation and chemotherapy agent infusion.&#xD;
      This is a single-center, double-blind, randomized, placebo-controlled study comparing the&#xD;
      effect of intravenously infused nitroglycerin and saline on the incidence of the&#xD;
      cardio-respiratory side effect in pediatric retinoblastoma patients undergoing intra-arterial&#xD;
      chemotherapy. Prior to the procedure, each patient will be randomized into either the&#xD;
      control-first arm, saline, or study-first arm, nitroglycerin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prior to the procedure, each patient will be randomized into either the saline-first arm or nitroglycerin-first arm.&#xD;
At the first intra-arterial chemotherapy after enrollment, saline or nitroglycerin is used according to the group allocation.&#xD;
At the second intra-arterial chemotherapy after enrollment, nitroglycerin is used for the saline-first arm, and saline is used for the nitroglycerin-first arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of the cardio-respiratory side effects during ophthalmic artery selection and intra-arterial injection of chemotherapy agents. (percent)</measure>
    <time_frame>During the intra-arterial chemotherapy (up to 4 hour)</time_frame>
    <description>Bradycardia (&lt; 80% of Baseline), Hypotension (&lt; 80% of Baseline), Decrease in the lung compliance, Abnormal end-tidal CO2 curve, or Desaturation (SpO2 &lt;95%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of the cardio-respiratory side effects during ophthalmic artery selection and intra-arterial injection of chemotherapy agents. (percent)</measure>
    <time_frame>During and after the intra-arterial chemotherapy (up to 48 hour)</time_frame>
    <description>Duration between the onset and the recovery from cardio-respiratory side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of using vaso-active drugs (percent)</measure>
    <time_frame>During and after the intra-arterial chemotherapy (up to 48 hour)</time_frame>
    <description>The incidence of using vaso-active drugs (e.g. vasopressor, inotropics)(percent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the side effect of nitroglycerin infusion (percent)</measure>
    <time_frame>During the intra-arterial chemotherapy (up to 4 hour)</time_frame>
    <description>Hypotension (&lt; 80% of baseline) after 10 minutes from nitroglycerin infusion, or allergic reaction, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concentration of inhaled sevoflurane (vol%)</measure>
    <time_frame>During the intra-arterial chemotherapy (up to 4 hour)</time_frame>
    <description>The concentration of inhaled sevoflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The depth of anesthesia</measure>
    <time_frame>During the intra-arterial chemotherapy (up to 4 hour)</time_frame>
    <description>The depth of anesthesia (bispectral index or patient sedation index, 0-100, 0 smaller score means deep anesthesia and larger score means awake state.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of anesthesia (min)</measure>
    <time_frame>During the intra-arterial chemotherapy (up to 4 hour)</time_frame>
    <description>Duration of anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time (min)</measure>
    <time_frame>During the intra-arterial chemotherapy (up to 4 hour)</time_frame>
    <description>From ophthalmic artery selection to the end of intra-arterial injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The procedural satisfaction score of radiologist (1-3)</measure>
    <time_frame>During the intra-arterial chemotherapy (up to 4 hour)</time_frame>
    <description>3 grades (1:poor, 2:fair, 3:good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the newly developed focal ischemia or infarct in retina photography(yes or no)</measure>
    <time_frame>After the intra-arterial chemotherapy (up to 6 month)</time_frame>
    <description>Incidence of the newly developed focal ischemia or infarct in retina photography(yes or no) on ophthalmology outpatient clinic after the intra-arterial chemotherapy assessed by pediatric ophthalmologist</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Nitroglycerin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.</description>
    <arm_group_label>Nitroglycerin</arm_group_label>
    <other_name>Intravenous nitroglycerin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Intravenous normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Retinoblastoma patients who need intra-arterial chemotherapy under general anesthesia&#xD;
&#xD;
          -  Residual intra-arterial chemotherapy â‰¥ 2 times (cross-over design)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Respiratory disease causing a decrease in lung compliance&#xD;
&#xD;
          -  Unstable vital sign, significant arrhythmia or hypotension, Shock&#xD;
&#xD;
          -  Hypersensitivity or contraindication to nitroglycerin&#xD;
&#xD;
          -  Increased intracranial pressure, Intracranial hemorrhage&#xD;
&#xD;
          -  Recent use of PDE5 inhibitors (&lt;24 hours after sildenafil or vardenafil; &lt;48 hours&#xD;
             after tadalafil)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young-Eun Jang, MD</last_name>
    <phone>82-2-2072-3664</phone>
    <email>na0ag2@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin-Tae Kim, MD, PhD</last_name>
    <phone>82-2-2072-3664</phone>
    <email>jintae73@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jin-Tae Kim</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Tae Kim, MD. PhD</last_name>
      <phone>82-2-2072-3295</phone>
      <email>kimjintae73@dreamwiz.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>FRAYSER R, HICKAM JB. EFFECT OF VASODILATOR DRUGS ON THE RETINAL BLOOD FLOW IN MAN. Arch Ophthalmol. 1965 May;73:640-2.</citation>
    <PMID>14281979</PMID>
  </reference>
  <reference>
    <citation>Yaster M, Simmons RS, Tolo VT, Pepple JM, Wetzel RC, Rogers MC. A comparison of nitroglycerin and nitroprusside for inducing hypotension in children: a double-blind study. Anesthesiology. 1986 Aug;65(2):175-9.</citation>
    <PMID>3090906</PMID>
  </reference>
  <reference>
    <citation>Dorner GT, Garhofer G, Kiss B, Polska E, Polak K, Riva CE, Schmetterer L. Nitric oxide regulates retinal vascular tone in humans. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H631-6. Epub 2003 May 15.</citation>
    <PMID>12750062</PMID>
  </reference>
  <reference>
    <citation>Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011 Mar;31(3):566-73. doi: 10.1097/IAE.0b013e318203c101.</citation>
    <PMID>21273941</PMID>
  </reference>
  <reference>
    <citation>Shields CL, Bianciotto CG, Jabbour P, Ramasubramanian A, Lally SE, Griffin GC, Rosenwasser R, Shields JA. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011 Nov;129(11):1399-406. doi: 10.1001/archophthalmol.2011.150. Epub 2011 Jun 13.</citation>
    <PMID>21670328</PMID>
  </reference>
  <reference>
    <citation>Shields CL, Bianciotto CG, Jabbour P, Griffin GC, Ramasubramanian A, Rosenwasser R, Shields JA. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol. 2011 Nov;129(11):1407-15. doi: 10.1001/archophthalmol.2011.151. Epub 2011 Jun 13.</citation>
    <PMID>21670326</PMID>
  </reference>
  <reference>
    <citation>Fallaha N, Dubois J, Carret AS, Callejo SA, Hamel P, Superstein R. Real-time ophthalmoscopic findings of intraophthalmic artery chemotherapy in retinoblastoma. Arch Ophthalmol. 2012 Aug;130(8):1075-7. doi: 10.1001/archophthalmol.2012.180.</citation>
    <PMID>22893086</PMID>
  </reference>
  <reference>
    <citation>Cugati S, Varma DD, Chen CS, Lee AW. Treatment options for central retinal artery occlusion. Curr Treat Options Neurol. 2013 Feb;15(1):63-77. doi: 10.1007/s11940-012-0202-9.</citation>
    <PMID>23070637</PMID>
  </reference>
  <reference>
    <citation>Phillips TJ, McGuirk SP, Chahal HK, Kingston J, Robertson F, Brew S, Roebuck D, Hungerford JL, Herod J. Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma. Paediatr Anaesth. 2013 Oct;23(10):940-5. doi: 10.1111/pan.12162. Epub 2013 May 13.</citation>
    <PMID>23668238</PMID>
  </reference>
  <reference>
    <citation>Kato MA, Green N, O'Connell K, Till SD, Kramer DJ, Al-Khelaifi M, Han JH, Pryor KO, Gobin YP, Proekt A. A retrospective analysis of severe intraoperative respiratory compliance changes during ophthalmic arterial chemosurgery for retinoblastoma. Paediatr Anaesth. 2015 Jun;25(6):595-602. doi: 10.1111/pan.12603. Epub 2015 Jan 7.</citation>
    <PMID>25565164</PMID>
  </reference>
  <reference>
    <citation>Scharoun JH, Han JH, Gobin YP. Anesthesia for Ophthalmic Artery Chemosurgery. Anesthesiology. 2017 Jan;126(1):165-172.</citation>
    <PMID>27748655</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin-Tae Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Intra-arterial chemotherapy</keyword>
  <keyword>Cardio-respiratory side effects</keyword>
  <keyword>Nitroglycerin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

